Real-world effectiveness of clozapine in patients with bipolar disorder: Results from a 2-year mirror-image study

Bipolar Disorders

Volumn 14, Issue 8, 2012, Pages 863-869

  Nielsen, Jimmi ^a   Kane, John M ^b,c   Correll, Christoph U ^b,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic agents; Bipolar disorder; Clozapine; Effectiveness; Mood stabilizer; Treatment resistance

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLOZAPINE; DIURETIC AGENT; LAMOTRIGINE; LITHIUM; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

AGRANULOCYTOSIS; ARTICLE; BIPOLAR DISORDER; CARDIOMYOPATHY; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ICD-10; ILEUS; MAJOR CLINICAL STUDY; MALE; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT DURATION;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLOZAPINE; DENMARK; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTPATIENTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84869830384     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12018     Document Type: Article

References (34)

1. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacol 2011; 36: 375-389.
2. Fountoulakis KN, Kasper S, Andreassen O et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2012; 262(Suppl. 1): 1-48.
3. McIntyre RS, Muzina DJ, Adams A et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother 2009; 10: 3061-3075.
4. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull 2012; 38: 592-598.
5. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacol 2010; 35: 1997-2004.
6. Nielsen J, Foldager L, Meyer JM. Increased use of antibiotics in patients treated with clozapine. Eur Neuropsychopharmacol 2009; 19: 483-486.
7. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12, 760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576-580.
8. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother 2007; 7: 829-839.
9. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
10. Frye MA, Ketter TA, Altshuler LL et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48: 91-104.
11. Hummel B, Dittmann S, Forsthoff A, Matzner N, Amann B, Grunze H. Clozapine as add-on medication in the maintenance treatment of bipolar and schizoaffective disorders. A case series. Neuropsychobiol 2002; 45(Suppl. 1): 37-42.
12. Gupta M. Clozapine monotherapy for 66months in treatment resistant bipolar disorder: a case report. J Clin Psychopharmacol 2009; 29: 501-503.
13. Chang JS, Ha KS, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006; 67: 461-467.
14. Kant R, Chalansani R, Chengappa KN, Dieringer MF. The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder. J Child Adolesc Psychopharmacol 2004; 14: 57-63.
15. Degner D, Bleich S, Muller P, Hajak G, Adler L, Ruther E. Clozapine in the treatment of mania. J Neuropsychiatry Clin Neurosci 2000; 12: 283.
16. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61: 638-642.
17. Calabrese JR, Kimmel SE, Woyshville MJ et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-764.
18. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003; 64: 451-458.
19. Suppes T, Ozcan ME, Carmody T. Response to clozapine of rapid cycling versus non-cycling patients with a history of mania. Bipolar Disord 2004; 6: 329-332.
20. Green AI, Tohen M, Patel JK et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000; 157: 982-986.
21. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164-1169.
22. Barbini B, Scherillo P, Benedetti F, Crespi G, Colombo C, Smeraldi E. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol 1997; 12: 109-112.
23. Munk-Jorgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull 1997; 44: 82-84.
24. WHO. World Health Organization, Collaborating Centre Drug Statistics Methodology, 2012. Available from: http://www.whocc.no/atc_ddd_index/ [accessed 10 October 2012].
25. Nielsen J, le Quach P, Emborg C, Foldager L, Correll CU. 10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 2010; 122: 356-366.
26. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010; 24: 965-971.
27. Uggerby P, Nielsen RE, Correll CU, Nielsen J. Characteristics and predictors of long-term institutionalization in patients with schizophrenia. Schizophr Res 2011; 131: 120-126.
28. Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol 2012; 32: 678-683.
29. Dion GL, Tohen M, Anthony WA, Waternaux CS. Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry 1988; 39: 652-657.
30. Abood Z, Sharkey A, Webb M, Kelly A, Gill M. Are patients with bipolar affective disorder socially disadvantaged? A comparison with a control group. Bipolar Disord 2002; 4: 243-248.
31. Nielsen J, Munk-Jorgensen P, Skadhede S, Correll CU. Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study. J Clin Psychiatry 2011; 72: 140-143.
32. Tang YL, Mao P, Li FM et al. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol 2007; 64: 49-56.
33. Citrome L, Reist C, Palmer L et al. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res 2009; 108: 238-244.
34. Nooijen PM, Carvalho F, Flanagan RJ. Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol 2011; 26: 112-119.